Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - The company, Absci, is a generative AI drug creation firm that is entering a new era with molecules designed by its AI moving into clinical trials, with proof of concept expected within 24 months for two Phase II readouts in androgenic alopecia and endometriosis [1][2] Group 1: AI in Drug Discovery - The company aims to industrialize AI for drug discovery, leveraging AI to identify target biology and design molecules [2] - A new model, Origin-1, has been announced, which enhances the AI's capabilities through a wet lab in the loop approach [2] - The company has a rapid 6-week cycle time for validating its models with real-world data, facilitating informed decision-making regarding biological targets [2]